[Side effect of metrizamide and meglumine iocarmate in lumbar myelography. A prospective, parallel, interview study (author's transl)].
Side effects of metrizamide (Amipaque) and meglumine iocarmate (Dimer-X) were compared in lumbar myelography of 161 patients by a prospective, parallel, interview study. Severe complications were not observed. The percentage pairs of smaller complications were mainly in favour of Dimer-X, but in 2 of the 54 pairs only the difference did raise to a significant level. In one pair there were less symptomless patients after Amipaque-myelography (p less than 0.05) and in another pair the men had more headache after Amipaque-myelography (p less than 0.01). It may be possible to show with larger comparative series, that Amipaque has a tendency to cause more central-subcortical or meningeal-side effects than Dimer-X.
D005260:Female; D005387:Finland; D006801:Humans; D007482:Iothalamate Meglumine / Q000009:adverse effects*; D008159:Lumbar Vertebrae; D008297:Male; D008793:Metrizamide / Q000009:adverse effects*; D009192:Myelography / Q000009:adverse effects*; D011446:Prospective Studies
D008793:Metrizamide; D007482:Iothalamate Meglumine
Die Nebenwirkungen von Metrizamid und Meglumin-locarmat bei der lumbalen Myelographie. Eine prospektive, parallele Interviewstudie.